Search

everythinglearnresearchcommunity

for

Search:↓

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

Analyzing data on pyrilutamide, a potential hair loss treatment, as well as the effectiveness of other treatments such as Minoxidil, Finasteride, and RU58841.

PP405 updates are seen as vague and lacking substance, causing frustration among users. Some users report positive effects from using minoxidil and dutasteride, while others remain skeptical about new treatments.

The conversation discusses alternatives to finasteride for hair loss, including topical treatments like minoxidil, RU58841, CB-03-01, and dutasteride. Users also mention other options like alfatradiol, topical caffeine, and mesotherapy, while expressing concerns about side effects and the effectiveness of these treatments.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

The user experienced chest soreness and mild gynecomastia after taking 1mg finasteride three times a week, which resolved after stopping the medication. They are considering trying a lower dose or topical finasteride to avoid side effects.

Current treatments like finasteride, minoxidil, and derma rolling are considered the best for hair loss, while new treatments such as GT20029, PP405, and others are in various trial phases with results expected in the coming years. There is cautious optimism about the affordability and effectiveness of these upcoming treatments.

PP405 is a potential hair loss treatment showing promise, especially for men with severe balding. Some are hopeful it will be a game-changer for those who cannot tolerate finasteride or minoxidil, despite skepticism about the outcomes.

The conversation discusses hair loss treatments, specifically RU58841, with mentions of side effects from finasteride and dutasteride. Alternatives like Pyri, KX-826, and Breezula are also mentioned.

The user is trying RU58841, oral minoxidil, and dermarolling to combat hair loss caused by increased scalp testosterone after using finasteride and dutasteride. They plan to document their results.

Topical finasteride concentrations and application amounts are debated, with concerns that mainstream solutions may use arbitrary concentrations. A 0.25% solution with a specific application method is suggested as more appropriate than higher concentrations.

The user is taking 1mg finasteride daily and RU58841 5% but still experiencing hair loss. They are considering adding topical finasteride or switching to dutasteride, and are not planning to use minoxidil until hair loss stabilizes.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

The user maintained hair with minoxidil, alfatradiol, and fluridil after stopping finasteride due to erectile dysfunction. They recently added pyrilutamide and are seeking feedback on its effectiveness after six months of use.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

The conversation discusses the use of finasteride for hair loss, with OP considering switching to dutasteride due to concerns about effectiveness. Users share experiences and concerns about side effects, including potential impacts on fertility.

A user stopped oral finasteride after 7 years due to decreased libido and switched to topical finasteride and minoxidil. Others shared similar experiences and discussed alternatives like dutasteride and topical treatments.

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

The user is considering switching from finasteride to oral dutasteride due to side effects and lack of regrowth. They are unable to access topical dutasteride and are seeking advice on whether to proceed with oral dutasteride.

Dutasteride may cause chronic infertility by reducing semen volume and motility, with concerns about irreversible prostate fibrosis. Users consider switching to finasteride or using treatments like minoxidil and microneedling, weighing hair preservation against fertility.

The conversation discusses using scalp antiandrogens like RU58841, pyrilutamide, or fluridil on the face to reduce sebum production, noting that clascoterone (winlevi) is an approved facial antiandrogen with underwhelming reviews.

The conversation is about the effectiveness and production of GT20029, a drug being developed as a topical androgen receptor degrader for hair loss, and whether it can fully degrade androgen receptors or only partially. It also discusses the drug's potential unique working mechanism and synthesis by a company called Anagen.

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.

Men discussing hair loss treatments, including bicalutamide, cyproterone acetate, dutasteride, minoxidil, and RU58841. They share experiences and concerns about side effects like infertility, liver health, and feminization.

The user used 0.5 mL of 0.5 mg of Pyrilutamide for 60 days for hair loss, but didn't notice any hair growth. They shared their hormone panel results and are seeking advice on next steps.

The conversation is about personal experiences with Anagenic Pyrilutamid for hair loss and what carriers people use with it. No specific treatments or outcomes are mentioned.

The conversation discusses hair loss treatments, with users mentioning dutasteride (Dut) as effective and wishing for more accessible dosages. They also debate the components of the "big 3" treatments, which now include Dut, RU58841, and oral minoxidil, with finasteride and minoxidil being consistently mentioned.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

The conversation discusses hair loss treatments, including dutasteride, oral minoxidil, finasteride, and potential additions like topical finasteride, minoxidil, micro-needling, and topical anti-androgens such as RU58841. The effectiveness and worth of these treatments, including localized dutasteride mesotherapy, are considered.

Hair loss treatments including Minoxidil, Finasteride and RU58841; with a focus on Pyrilutamide could potentially be used as an effective treatment.